Product Code : Hepcinat
Brand Name : Hepcinat
- Unit of Measure
- Price Range
- - USD ($)
- Payment Terms
- Cash on Delivery (COD), Letter of Credit (L/C), Letter of Credit at Sight (Sight L/C), Telegraphic Transfer (T/T), Western Union, Paypal, Others
- Supply Ability
- 1 Per Day
- Delivery Time
- Sample Policy
- Contact us for information regarding our sample policy
- Packaging Details
- 1 x 30
- Main Export Market(s)
- Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
Hepcinat Sovaldi (Sofosbuvir) is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon.
Hepcinat Sovaldi (Sofosbuvir) is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, among the second generation of protease inhibitors that directly attack the Hep C virus cell.
These are the highlights of Sovaldi (Sofosbuvir):
Hepcinat 400mg tablet, once-daily oral dose. *See below for recommended regimens.
*Hepcinat Sovaldi (Sofosbuvir) approved for use in Genotypes 1, 2, 3, or 4
*Hepcinat High Cure Rates with an overall response rate of 90% in most gentotypes.
*Hepcinat Shortened 12 Week Course of Therapy for Many Patients.
*Hepcinat First Ever Oral Treatment Regimen for Genotypes 2 or 3. *See below for recommended regimens.
*Hepcinat First Regimen for Patients Awaiting Liver Transplantation to Prevent HCV Recurrence.
Recommended regimens and treatment duration for Sovaldi (Sofosbuvir) combination therapy in HCV mono-infected or HCV/HIV-1 co-infected patients follows:
Genotype 1 or 4
Treatment: Hepcinat Sovaldi (Sofosbuvir) + Peg-interferon alfa + ribavirin
Duration: 12 weeks
Treatment:Hepcinat Sovaldi (Sofosbuvir) + ribavirin
Duration: 12 weeks
Treatment: Hepcinat (Solvaldi Sofosbuvir) + ribavirin
Duration: 24 weeks
Hepcinat Sovaldi (Sofosbuvir) can be considered for (CHC) chronic hepatitis C patients with genotype 1 infection in combination with ribavirin for 24 weeks for those patients who are interferon ineligible.
Additionally, Hepcinat Sovaldi (Sofosbuvir) should be used in combination with ribavirin for treatment of CHC patients with hepatocelluar carcinoma (liver cancer) awaiting liver transplantation for up to 48 weeks or until liver transplant to prevent post-transplant HCV infection.
Treatment regimen, duration and response to Hepcinat Sovaldi (Sofosbuvir) are dependent on viral genotype and patient population, and associated baseline factors. Monotherapy is not recommended.
Side effects of Hepcinat Sovaldi (Sofosbuvir) Most Common:
Hepcinat Sovaldi +peginterferon alfa + ribavirin combination therapy were fatigue, headache, nausea, insomnia, and anemia.
Hepcinat Sovaldi +ribavirin combination therapy were fatigue and headache.